What does Protalix BioTherapeutics, Inc. do?
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the…
What is Protalix BioTherapeutics, Inc.'s P/E and P/B ratio?
Protalix BioTherapeutics, Inc. has a P/E ratio of 11.2 and a P/B ratio of 2.90.
What is Protalix BioTherapeutics, Inc.'s debt-to-equity ratio?
Protalix BioTherapeutics, Inc. has a debt-to-equity ratio of 0.13.
How much does Protalix BioTherapeutics, Inc. owe compared with what it owns?
Protalix BioTherapeutics, Inc. owes $0.35 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Protalix BioTherapeutics, Inc.'s Positivity rank?
Protalix BioTherapeutics, Inc. is ranked #3,476 of 6,774 companies globally and #1,500 of 4,000 in United States on PositoAI, with a Positivity Score of 20,537.
Does Protalix BioTherapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Protalix BioTherapeutics, Inc..
Where can I read the latest news about Protalix BioTherapeutics, Inc.?
Recent headlines about Protalix BioTherapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Protalix BioTherapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Protalix BioTherapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.